Freeline to Participate in Evercore ISI 4th Annual HealthCONx Conference
23 nov. 2021 16h01 HE
|
Freeline Therapeutics
LONDON, Nov. 23, 2021 (GLOBE NEWSWIRE) -- Freeline Therapeutics Holdings plc (Nasdaq: FRLN) (the “Company” or “Freeline”), a clinical-stage biotechnology company developing transformative...
Freeline to Participate in Stifel 2021 Virtual Healthcare Conference
10 nov. 2021 16h01 HE
|
Freeline Therapeutics
LONDON, Nov. 10, 2021 (GLOBE NEWSWIRE) -- Freeline Therapeutics Holdings plc (Nasdaq: FRLN) (the “Company” or “Freeline”), a clinical-stage biotechnology company developing transformative...
Freeline Reports New Data from Fabry Disease Program, Pipeline and Company Updates, Including Appointment of Pamela Foulds, MD as Chief Medical Officer, and Third Quarter 2021 Financial Results
09 nov. 2021 16h01 HE
|
Freeline Therapeutics
Lowest dose cohort of MARVEL-1 trial of FLT190 for Fabry disease demonstrates durable α-Gal A expression over two years in the first patient and promising efficacy with near normal α-Gal A levels in...
Freeline Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
03 nov. 2021 16h01 HE
|
Freeline Therapeutics
LONDON, Nov. 03, 2021 (GLOBE NEWSWIRE) -- Freeline Therapeutics Holdings plc (Nasdaq: FRLN) (the “Company” or “Freeline”), a clinical-stage biotechnology company developing transformative...
Freeline to Participate in Upcoming Investor Conferences in September 2021
07 sept. 2021 07h00 HE
|
Freeline Therapeutics
LONDON, Sept. 07, 2021 (GLOBE NEWSWIRE) -- Freeline Therapeutics Holdings plc (Nasdaq: FRLN) (the “Company” or “Freeline”), a clinical-stage biotechnology company developing transformative...
Freeline Appoints Michael J. Parini as Chief Executive Officer and Reports Second Quarter 2021 Financial Results
16 août 2021 07h00 HE
|
Freeline Therapeutics
On track for three programs in the clinic by year end; trial site initiation for FLT180a for Hemophilia B and FLT201 for Gaucher disease Type 1 expected by year end; program for FLT190 for Fabry...
Freeline Provides Executive Leadership Team Update; Company to Provide Corporate Update and Second Quarter 2021 Financial Results on Monday, August 16
13 août 2021 06h30 HE
|
Freeline Therapeutics
LONDON, Aug. 13, 2021 (GLOBE NEWSWIRE) -- Freeline Therapeutics Holdings plc (Nasdaq: FRLN) (the “Company” or “Freeline”), a clinical-stage biotechnology company developing transformative...
Freeline Announces Executive Leadership Changes
30 juin 2021 16h01 HE
|
Freeline Therapeutics
Appointment of Chief Technical Operations Officer James Bircher continues evolution of leadership team to execute across near- and long-term priorities Amit Nathwani, MD, PhD to return to Chief...
Freeline Doses Second Patient of Phase 1/2 MARVEL-1 Clinical Trial for Fabry Disease
16 juin 2021 07h00 HE
|
Freeline Therapeutics
Lowest dose cohort complete and study positioned for dose escalation Company to present FLT190 data by year-end LONDON, June 16, 2021 (GLOBE NEWSWIRE) -- Freeline Therapeutics Holdings plc...
Freeline Reports First Quarter 2021 Financial Results and Recent Business Highlights
17 mai 2021 16h02 HE
|
Freeline Therapeutics
FLT190 Phase 1/2 dose-finding study in Fabry disease on track to dose additional patients; Company to present data by year-end FLT201 Phase 1/2 dose-finding study in Gaucher disease Type 1 expected...